LORAZEPAM

Search structure
Trade Names:
Synonyms:
Status: Approved (1977)
Entry Type: Small molecule
Molecule Category: Parent
ATC: N05BA06
UNII: O26FZP769L

Structure
InChI Key DIWRORZWFLOCLC-UHFFFAOYSA-N
Smile O=C1Nc2ccc(Cl)cc2C(c2ccccc2Cl)=NC1O
InChI
InChI=1S/C15H10Cl2N2O2/c16-8-5-6-12-10(7-8)13(19-15(21)14(20)18-12)9-3-1-2-4-11(9)17/h1-7,15,21H,(H,18,20)

Physicochemical Descriptors

Property Name Value
Molecular Formula C15H10Cl2N2O2
Molecular Weight 321.16
AlogP 3.1
Hydrogen Bond Acceptor 3.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 1.0
Polar Surface Area 61.69
Molecular species NEUTRAL
Aromatic Rings 2.0
Heavy Atoms 21.0

Pharmacology

Action Mechanism of Action Reference
POSITIVE ALLOSTERIC MODULATOR GABA-A receptor; anion channel positive allosteric modulator PubMed PubMed Wikipedia
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Auxiliary transport protein Fatty acid binding protein family
- - - 12900 -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Status Epilepticus 4 D013226 ClinicalTrials
Depressive Disorder 4 D003866 ClinicalTrials
Depressive Disorder 4 D003866 ClinicalTrials
Vertigo 3 D014717 ClinicalTrials
Dementia 3 D003704 ClinicalTrials
Schizophrenia 3 D012559 ClinicalTrials
Psychomotor Agitation 3 D011595 ClinicalTrials
Psychotic Disorders 3 D011618 ClinicalTrials
Epilepsia Partialis Continua 3 D017036 ClinicalTrials
Delirium 2 D003693 ClinicalTrials
Substance Withdrawal Syndrome 2 D013375 ClinicalTrials
Cocaine-Related Disorders 2 D019970 ClinicalTrials
Epilepsy, Reflex 2 D020195 ClinicalTrials
Seizures 2 D012640 ClinicalTrials
Pain 2 D010146 ClinicalTrials
Amphetamine-Related Disorders 2 D019969 ClinicalTrials
Epilepsy 2 D004827 ClinicalTrials
Alcoholism 2 D000437 ClinicalTrials
Alzheimer Disease 1 D000544 ClinicalTrials
Depressive Disorder, Major 1 D003865 ClinicalTrials
Substance-Related Disorders 1 D019966 ClinicalTrials
Voice Disorders 1 D014832 ClinicalTrials
Obsessive-Compulsive Disorder 1 D009771 ClinicalTrials

Related Entries

MCS

Scaffolds

Side Effects from Label

Side effects Relative Frequency (%) Labels
Cardiac disorders Dizziness 6.9
General disorders and administration site conditions Asthenia 4.2
Nervous system disorders Somnolence 3.75
Nervous system disorders Somnolence 3.53
General disorders and administration site conditions Balance disorder 3.4
Respiratory, thoracic and mediastinal disorders Hypoventilation 2.5
Respiratory, thoracic and mediastinal disorders Hypoxia 2.5
Metabolism and nutrition disorders Respiratory failure 2.5
Vascular disorders Hypotension 2.35
Metabolism and nutrition disorders Respiratory failure 2.35
Vascular disorders Hypotension 1.54
Metabolism and nutrition disorders Respiratory failure 1.54
Nervous system disorders Somnolence 1.54
Respiratory, thoracic and mediastinal disorders Apnoea 1.25
Nervous system disorders Coma 1.25
Nervous system disorders Headache 1.25
Blood and lymphatic system disorders Hypochromic anaemia 1.25
Blood and lymphatic system disorders Leukocytosis 1.25
Metabolism and nutrition disorders Respiratory failure 1.25
Blood and lymphatic system disorders Thrombocytosis 1.25
Respiratory, thoracic and mediastinal disorders Apnoea 1.18
Nervous system disorders Coma 1.18
Nervous system disorders Depressed level of consciousness 1.18
Nervous system disorders Headache 1.18
Respiratory, thoracic and mediastinal disorders Hypoventilation 1.18
Respiratory, thoracic and mediastinal disorders Hypoxia 1.18
Metabolism and nutrition disorders Respiratory failure 1.18
Nervous system disorders Stupor 1.18
Metabolism and nutrition disorders Acidosis 0.769
Renal and urinary disorders Bladder pain 0.769
Injury, poisoning and procedural complications Brain oedema 0.769
Nervous system disorders Coma 0.769
Convulsion 0.769
Infections and infestations Cystitis 0.769
Renal and urinary disorders Cystitis noninfective 0.769
Psychiatric disorders Hyperventilation 0.769
Respiratory, thoracic and mediastinal disorders Hypoventilation 0.769
Respiratory, thoracic and mediastinal disorders Hypoxia 0.769
Infections and infestations Infection 0.769
General disorders and administration site conditions Injection site reaction 0.769
Investigations Liver function test abnormal 0.769
Social circumstances Mental disability 0.769
Gastrointestinal disorders Nausea 0.769
Metabolism and nutrition disorders Respiratory failure 0.769
Nervous system disorders Thinking abnormal 0.769
Gastrointestinal disorders Vomiting 0.769
Vascular disorders Hypertension 0.1
Vascular disorders Hypotension 0.1

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Psychiatric disorders
22.58
Nervous system disorders
17.52
General disorders and administration site conditions
13.91
Injury, poisoning and procedural complications
10.44
Gastrointestinal disorders
4.52
Respiratory, thoracic and mediastinal disorders
4.09
Cardiac disorders
3.86
Vascular disorders
3.66
Investigations
3.35
Musculoskeletal and connective tissue disorders
3.01

Cross References

Resources Reference
CAS NUMBER 846-49-1
ChEBI 6539
ChEMBL CHEMBL580
DrugBank DB00186
DrugCentral 1606
EPA CompTox DTXSID7023225
FDA SRS O26FZP769L
Human Metabolome Database HMDB0014332
Guide to Pharmacology 5884
KEGG D00365
PharmGKB PA450267
PubChem 3958
SureChEMBL SCHEMBL26961
ZINC ZINC00896595
CONTENTS